Bill Burns nominated for election to Molecular Partners’ Board of Directors as Vice-Chairman with nomination to Chairman in 2018

By | Uncategorized | No Comments

The Board of Directors of Molecular Partners has nominated William (Bill) Burns, former CEO of Roche Pharmaceuticals, for election to the Board at an EGM on October 31, 2017, after which the Board of Directors plans to appoint him Vice-Chairman. At the EGM Patrick Amstutz, CEO of Molecular Partners, also stands for election to the Board.

Read More

Molecular Partners reports key financials and corporate highlights for H1 2017: Pipeline development on track with several key milestones ahead

By | Uncategorized | No Comments

Molecular Partners announced its results and highlights for H1 2017, a semester in which the company achieved two key clinical milestones: the completion of full enrollment in its two phase 3 clinical trials of abicipar in wet AMD, and the dosing of the first patient in the phase 2 trial of MP0250 in multiple myeloma. In addition, the company diversified its shareholder base through the acquisition of a substantial portion of the venture capital investors’ shareholdings by new private investors.

Read More